Skip to main content
Premium Trial:

Request an Annual Quote

Van Andel Institute, Spectrum Health Create Lab to Study Genomics, Proteomics of Disease

NEW YORK (GenomeWeb News) – The Van Andel Institute and Spectrum Health have started a molecular technologies lab that will study genomics and proteomics for application in cancer, heart disease, mental illness, and other diseases, Spectrum Health said today.
 
Spectrum, a non-profit group that operates seven hospitals in Western Michigan, said the Center for Molecular Medicine, located in Grand Rapids, has $6 million in funding.
 
The CMM will use Van Andel’s infrastructure and employees along with Spectrum’s clinical lab and research resources.
 
Van Andel CEO and Chairman David Van Andel said Spectrum has “a large patient population which allows us to apply what we're learning directly into the clinical setting."
 
The CMM will house and use DNA and RNA extraction, DNA microarrays, multiplex protein detection, and gene-expression profiling.
 
Directing the CMM will be Dan Farkas, who Spectrum said has established three other hospital-based molecular diagnostics labs.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.